Literature DB >> 9550428

Identification and characterization of multiple HLA-A24-restricted HIV-1 CTL epitopes: strong epitopes are derived from V regions of HIV-1.

Y Ikeda-Moore1, H Tomiyama, K Miwa, S Oka, A Iwamoto, Y Kaneko, M Takiguchi.   

Abstract

HIV-1-specific CTL has a crucial role in the elimination of the virus. However, a restricted number of common HLA class I alleles has been studied for their presentation of HIV-1 CTL epitopes. We have attempted to identify HIV-1 CTL epitopes presented by HLA-A*2402 using reverse immunogenetics. Fifty-three HLA-A*2402-binding HIV-1 peptides were used to induce specific CTL in PBL of four HIV-1-infected individuals carrying HLA-A24. Twelve peptides were strongly suggested to be HLA-A*2402-restricted HIV-1 CTL epitopes because these peptides induced the specific CTL that killed both the target cells pulsed with the specific peptides and those infected with the vaccinia HIV-1 recombinant virus in at least one HIV-1-infected individual. Of these epitopes, 11 were confirmed by the generation of the specific CTL clones. Six were the Env epitopes while three, one, and one were derived from Gag, Pol, and Nef proteins, respectively. Analysis of 12 HIV-1-infected individuals using these peptides showed that 5 derived from the Env protein and one from the Nef protein were strong epitopes. These strong epitopes were derived from the diverse region of HIV-1 while weak epitopes were conserved in the HIV-1 clade B strain. Analysis of CTL recognition of mutations in these strong epitopes suggested that the mutations in the Env epitopes may critically influence CTL recognition in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9550428

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

1.  Analysis of genetic variability within the immunodominant epitopes of envelope gp41 from human immunodeficiency virus type 1 (HIV-1) group M and its impact on HIV-1 antibody detection.

Authors:  J Dorn; S Masciotra; C Yang; R Downing; B Biryahwaho; T D Mastro; J Nkengasong; D Pieniazek; M A Rayfield; D J Hu; R B Lal
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety.

Authors:  Y Nakamoto; E Mizukoshi; H Tsuji; Y Sakai; M Kitahara; K Arai; T Yamashita; K Yokoyama; N Mukaida; K Matsushima; O Matsui; S Kaneko
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

3.  An efficient and versatile mammalian viral vector system for major histocompatibility complex class I/peptide complexes.

Authors:  Ai Kawana-Tachikawa; Mariko Tomizawa; Jun-Ichi Nunoya; Tatsuo Shioda; Atsushi Kato; Emi E Nakayama; Tetsuya Nakamura; Yoshiyuki Nagai; Aikichi Iwamoto
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

4.  A β-tubulin 5-derived peptide induces cytotoxic T lymphocytes restricted to the HLA-A24 allele in prostate cancer patients.

Authors:  Nobukazu Komatsu; Yasunobu Terasaki; Fukuko Moriya; Shigetaka Suekane; Masanori Noguchi; Satoru Todo; Kyogo Itoh; Shigeki Shichijo
Journal:  Exp Ther Med       Date:  2010-07-20       Impact factor: 2.447

5.  Host-specific adaptation of HIV-1 subtype B in the Japanese population.

Authors:  Takayuki Chikata; Jonathan M Carlson; Yoshiko Tamura; Mohamed Ali Borghan; Takuya Naruto; Masao Hashimoto; Hayato Murakoshi; Anh Q Le; Simon Mallal; Mina John; Hiroyuki Gatanaga; Shinichi Oka; Zabrina L Brumme; Masafumi Takiguchi
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

6.  Immunization of BLT Humanized Mice Redirects T Cell Responses to Gag and Reduces Acute HIV-1 Viremia.

Authors:  Daniel T Claiborne; Timothy E Dudek; Colby R Maldini; Karen A Power; Musie Ghebremichael; Edward Seung; Elizabeth F Mellors; Vladimir D Vrbanac; Katharine Krupp; Abigail Bisesi; Andrew M Tager; David M Knipe; Christian L Boutwell; Todd M Allen
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

7.  Different abilities of escape mutant-specific cytotoxic T cells to suppress replication of escape mutant and wild-type human immunodeficiency virus type 1 in new hosts.

Authors:  Mamoru Fujiwara; Junko Tanuma; Hirokazu Koizumi; Yuka Kawashima; Kazutaka Honda; Saori Mastuoka-Aizawa; Sachi Dohki; Shinichi Oka; Masafumi Takiguchi
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

8.  Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402.

Authors:  Toshiyuki Baba; Marimo Sato-Matsushita; Akira Kanamoto; Akihiko Itoh; Naoki Oyaizu; Yusuke Inoue; Yutaka Kawakami; Hideaki Tahara
Journal:  J Transl Med       Date:  2010-09-16       Impact factor: 5.531

9.  Distinct recognition of non-clade B human immunodeficiency virus type 1 epitopes by cytotoxic T lymphocytes generated from donors infected in Africa.

Authors:  L Dorrell; T Dong; G S Ogg; S Lister; S McAdam; T Rostron; C Conlon; A J McMichael; S L Rowland-Jones
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

10.  HLA-A*01:03, HLA-A*24:02, HLA-B*08:01, HLA-B*27:05, HLA-B*35:01, HLA-B*44:02, and HLA-C*07:01 monochain transgenic/H-2 class I null mice: novel versatile preclinical models of human T cell responses.

Authors:  Rachid Boucherma; Hédia Kridane-Miledi; Romain Bouziat; Michael Rasmussen; Tanja Gatard; Francina Langa-Vives; Brigitte Lemercier; Annick Lim; Marion Bérard; Lbachir Benmohamed; Søren Buus; Ronald Rooke; François A Lemonnier
Journal:  J Immunol       Date:  2013-06-17       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.